EMA Authorised: Amglidia (glibenclamide) — Ammtek

View source ↗

Summary

Amglidia (glibenclamide) has been authorised in the EU for diabetes mellitus as an orphan medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Amglidia (glibenclamide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Ammtek. Decision date: 05/12/2023. Orphan medicine